Loading…
← CockpitCompetitor Analysis › 688177.SS Bio-Thera Solutions, Ltd. Class AOpen in the cockpit ↗

Bio-Thera Solutions, Ltd. Class A688177.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Guangzhou biosimilar developer with multiple approved biosimilars including a bevacizumab copy sold in China and abroad.

≈ A Chinese Coherus BioSciences (biosimilars)Momentum weak 28
Mkt cap
$929M
US dollars, full cap
Free float
20%
of shares outstanding
$/day
$7.36M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-47.5 pp
WACC 8.1%
Hurdle
n/a
no reverse DCF
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥15.03
1D-3.8%
1W-14.9%
1M-16.0%
3M-28.3%
6M-23.2%
YTD-35.0%
1Y-43.4%
ATR %5.4%
52w lowhigh44.5% off high

What Bio-Thera Solutions does

Guangzhou biosimilar developer with multiple approved biosimilars including a bevacizumab copy sold in China and abroad.

Earns partly from selling its own biosimilars in China, and partly from licence fees, milestone payments and supply income from overseas partners that handle registration and sales in their regions. Biosimilars are copies of biologic drugs, which are made in living cells and so cannot be copied exactly like pills.

In one line: A Chinese Coherus BioSciences (biosimilars).

Products and services

  • Bevacizumab biosimilar
  • Adalimumab and other biosimilars
  • Novel biologics pipeline

Customers

  • Hospitals and oncology centers
  • Overseas licensing partners

Where it sits in the supply chain

  • Pharmaceuticals
  • Biologics
  • Biosimilars

What could go right

  • Global biosimilar licensing deals
  • Oncology biosimilar adoption

What could go wrong

  • Biosimilar price erosion
  • Regulatory approval delays

Moat: narrow (regulatory licence, scale). Approved biosimilar manufacturing plus global partner licensing deals are costly and slow to duplicate.

Headquarters: Guangzhou, China · Founded: 2003 · Employees: 1,426

Named competitors

Bio-Thera Solutions at a glance

Size Bio-Thera Solutions (688177.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $929M, the 2302nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥15.03 on 18 Nov 2026.

Performance Over six months the shares fell 23.2%, against -16.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 24.1% over the last twelve months (peer median +2.4%); the operating margin is -44.2% (peer median 8.8%).

Valuation It trades at 6.5× enterprise value to sales against a peer median of 3.8× (5th most expensive of 18).

Capital Return on invested capital runs 47.5 points below its cost of capital (8.1% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 84688177.SS 77
Six months, rebased to 100: Bio-Thera Solutions against the median of its 20 peers (local-currency closes).

Bio-Thera Solutions financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.05BCN¥933MCN¥741MCN¥703MCN¥454M
Revenue growth—+26%+5%+55%—
Gross profitCN¥874MCN¥668MCN¥467MCN¥467MCN¥233M
EBITDAn/a-CN¥303M-CN¥449M-CN¥380M-CN¥441M
Net income-CN¥441M-CN¥332M-CN¥510M-CN¥395M-CN¥480M
Free cash flow-CN¥255M-CN¥202M-CN¥202M-CN¥686M-CN¥646M
Capital expenditureCN¥279MCN¥122MCN¥127MCN¥262MCN¥259M
Total debtCN¥971MCN¥686MCN¥629MCN¥483MCN¥9.51M

Quarterly statements and history in the cockpit →

Bio-Thera Solutions competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-25%0%+25%0392006002523004011795600422MLTX603538IMTX25952005688553688759AKTS4565PGHL688177.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Bio-Thera Solutions is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×20×40×60×0392006002523004011795600422IMTX2595AKTS4565688177.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bio-Thera Solutions is the large dot.

Bio-Thera Solutions competitors and peer comparison

Head to head with its named competitors (688177.SS vs 2696.HK vs AMGN vs SDZ.SW)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Bio-Thera Solutions 688177.SS$929M-23%+24%-44%6.5×n/a
Shanghai Henlius Biotech 2696.HK$3.05B-39%+33%12%3.3×14.1%
Amgen AMGN$240B+34%+9%36%7.2×1.6%
Sandoz SDZ.SW$41.7B+26%+1%15%4.2×7.5%

How Bio-Thera Solutions compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bio-Thera Solutions against its 20 peers (data as of 18 Nov 2026)
Measure688177.SSPeer medianRank in peer set
1-month return-16.0%-9.1%5th lowest of 21
6-month return-23.2%-16.9%9th lowest of 20
Distance from 52-week high-44.5%-48.9%10th highest of 21
Revenue growth (TTM)+24.1%+2.4%4th highest of 18
Operating margin-44.2%8.8%4th lowest of 18
EV / Sales6.5×3.8×5th most expensive of 18
ROIC minus cost of capital-47.5 pp-1.1 pplowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%6.5×n/an/a
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%4.5×10.3%-13.7%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%5.2×9.1%+13.4%
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%2.6×-3.7%+13.8%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%1.8×n/an/a
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%2.8×7.7%-6.9%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%3.8×11.6%+4.9%
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%2.0×17.6%+7.8%
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
SSY 2005.HKHong Kong$948M+8%-4%12%2.2×2.3%-0.5%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%2.5×n/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
Nxera Pharma 4565.TJapan$974M+46%+24%14%5.4×17.7%+27.3%
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%6.3×5.6%+9.3%

Questions

Who are Bio-Thera Solutions's main competitors?
Named competitors: Henlius Biotech (2696.HK), Amgen (AMGN), Sandoz (SDZ.SW). The cockpit's measured peer set (industry) also includes Oscotec (039200.KS), Guangxi Wuzhou Zhongheng (600252.SS), Zhejiang Garden Biopharmaceutical (300401.SZ), Lotus Pharmaceutical (1795.TW), KPC Pharmaceuticals (600422.SS), MoonLake Immunotherapeutics (MLTX).
Is Bio-Thera Solutions expensive compared with its peers?
On ev / sales it trades at 6.5× against a peer median of 3.8×, 5th most expensive of 18 in its peer set.
How has Bio-Thera Solutions stock performed?
Over six months to 18 Nov 2026 the shares returned -23.2% against -16.9% for the median peer; over one year -43.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.